Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to invite investors to a webinar on April 24, 2024 at 4:15 p.m.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, April 23, 2024
Information
Tags: 
Oncology, Health, Hospitals, General Health, Pharmaceutical, Biotechnology, Q&A
Geotags: 
UNITED STATES, NORTH AMERICA, CALIFORNIA
⚠ partially generated by AI ↴
Organisation: 
CALIDI BIOTHERAPEUTICS, CALIDI BIOTHERAPEUTICS, INC.
Stock Symbol: 
NYSEAM:CLDI
Summary
Key Points: 
  • Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to invite investors to a webinar on April 24, 2024 at 4:15 p.m.
  • The exclusive event, hosted by RedChip Companies, will feature Calidi Biotherapeutics Chief Business Officer, Stephen Thesing, Chief Scientific Officer, Antonio F. Santidrian, Ph.D., and Chief Financial Officer, Andrew Jackson, who will share insight into the Company’s proprietary technology platforms and current development pipeline.
  • A live Q&A session will follow the presentation.
  • To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_qT-PBRbTQ0yLeBbJ4jzPSw#/regi...
    Questions can be pre-submitted to [email protected] or online during the live event.


Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to invite investors to a webinar on April 24, 2024 at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature Calidi Biotherapeutics Chief Business Officer, Stephen Thesing, Chief Scientific Officer, Antonio F. Santidrian, Ph.D., and Chief Financial Officer, Andrew Jackson, who will share insight into the Company’s proprietary technology platforms and current development pipeline. A live Q&A session will follow the presentation.

To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_qT-PBRbTQ0yLeBbJ4jzPSw#/registration

Questions can be pre-submitted to [email protected] or online during the live event.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

Forward-Looking Statements

This press release may contain forward-looking statements for purposes of the "safe harbor" provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as "anticipates," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predicts," "project," "should," "towards," "would" as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company’s Form 10-K filed on March 15, 2024 and Final Prospectus filed on April 17, 2024.

Copyright: 
Copyright Business Wire 2024